retatrutide clinical data Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide FDA Approval Status 2026:

Avoiding excessively rapid weight loss (no more than 2% of body weight per week sustained)

The slow ladder lets the gut adapt, which is why side effects are dose-dependent and mostly early

Ro wants to empower anyone considering GLP-1s to take control of their health

*Correspondence: Roberta Poli, [email protected] These authors have contributed equally to this work and share first authorship This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Retatrutide is supplied as a lyophilized powder and should be reconstituted with bacteriostatic water (BAC water) immediately before use

Tirzepatide delivers stronger results but costs more